TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 343032
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg of aspirin
Study: 343032
Drug: 65 mg
Normalized name: opium 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg of propoxyphene HCl
Study: 31941553
Drug: Wearing habitual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearing habitual correction (cc)
Study: 31941553
Drug: Wearing habitual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearing habitual correction (cc) for IED detection
Study: 31464100
Drug: Nutritional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional care as per the algorithm (oral supplements, nasogastric feeds, and/or parenteral nutrition)
Study: 27525497
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (supination sugar-tong splinting)
Study: 27525497
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (DRUJ transfixation)
Study: 27525497
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (arthroscopic triangular fibrocartilage complex repair)
Study: 19882460
Drug: Drug users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug users not participating in the research
Study: 12213743
Drug: Intravenous triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous triiodothyronine administration (bolus followed by 6 hours infusion)
Study: 8591798
Drug: Single-dose L-dopa/benserazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose L-dopa/benserazide (300/75 mg)
Study: 2677988
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for bone metastasis
Study: 2677988
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for lung cancer patients with bone metastasis
Study: 934556
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics alone
Study: 934556
Drug: T-tube suction
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-tube suction drainage and prophylactic antibiotics in combination
Study: 31739177
Drug: <7/7 intended
Approvals — FDA: no, EMA: no, PMDA: no
Description: <7/7 intended doses (ID)
Study: 19622782
Drug: Low-dose rosiglitazone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rosiglitazone (4 mg/day)
Study: 19622782
Drug: High-dose rosiglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rosiglitazone (8 mg/day)
Study: 19622782
Drug: High-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metformin (2,000 mg/day)
Study: 19622782
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination rosiglitazone-metformin therapy (4 mg + 1,000 mg/day)
Study: 19622782
Drug: High-dose rosiglitazone-metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rosiglitazone-metformin combination therapy (8 mg + 2,000 mg/day)
Study: 7488475
Drug: Extradural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural morphine 2 mg (group M)
Study: 7488475
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine 10 ml (group L)
Study: 7488475
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine 2 mg and 2% lignocaine 10 ml (group ML)
Study: 8349939
Drug: Bumetanide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (2 mg)
Study: 6167346
Drug: Lower dosage
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dosage of vinblastine (0.3 mg/kg)
Study: 6167346
Drug: Four courses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four courses of remission induction therapy
Study: 26375942
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg once daily for 2 weeks followed by raltegravir 400 mg twice daily for 5 days
Study: 26375942
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily for 5 days
Study: 22650964
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of vitamin B12 (1 mg/day in weeks 1-8 and 1 mg/week in weeks 9-52)
Study: 22650964
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of vitamin B12 (1 mg on alternate days in weeks 1 and 2, 1 mg/week in weeks 3-8, and 1 mg/month in weeks 9-52)
Study: 22650964
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and intramuscular administration
Study: 15067411
Drug: Optical rhinometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optical rhinometry during negative provocation tests with control solution
Study: 11233800
Drug: Gemifloxacin (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin (320 mg orally for 7 days)
Study: 11233800
Drug: Placebo (matched,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched, once daily for 7 days)
Study: 8894914
Drug: Biofeedback-assisted relaxation
Normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biofeedback-assisted relaxation therapy
Study: 26281833
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of 1.0 Gy applied in 6 fractions of 1.0 Gy twice weekly (total dose 6.0 Gy)
Study: 26281833
Drug: Low single
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low single doses of 0.5 Gy applied in 12 fractions of 0.5 Gy three times weekly (total dose 6.0 Gy)
Study: 19686527
Drug: MET +
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MET + Cognitive-Behavioral Therapy (CBT)
Study: 17942927
Drug: Zanolimumab (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanolimumab (human IgG1 antibody against CD4)
Study: 15562884
Drug: Combined ibuprofen/pseudoephedrine/chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ibuprofen/pseudoephedrine/chlorpheniramine (200/30/2 mg)
Study: 15562884
Drug: Combined ibuprofen/pseudoephedrine/chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ibuprofen/pseudoephedrine/chlorpheniramine (400/60/4 mg)
Study: 15562884
Drug: Combined pseudoephedrine/chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pseudoephedrine/chlorpheniramine (30/2 mg)
Study: 11146707
Drug: Combined outreach
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined outreach initiative for pneumococcal and influenza vaccines
Study: 11146707
Drug: Combined outreach
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined outreach initiative targeted to people who had never received the pneumococcal vaccine or who had not received the influenza vaccine in the previous year
Study: 7870348
Drug: Controlled Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled Protein Diet (CPD) of 1 g protein/kg ideal body-weight/day
Study: 7870348
Drug: Low-Protein Diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Protein Diet (LPD) of 0.6 g protein/kg ideal body-weight/day
Study: 28166654
Drug: VM202 (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM202 (64 mg) administered by intramuscular injections on days 0, 7, 14, and 21.
Study: 28166654
Drug: VM202 (64
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM202 (64 mg) administered by intramuscular injections.
Study: 28166654
Drug: VM202 treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM202 treatment.
Study: 21931228
Drug: Tartary buckwheat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tartary buckwheat cookies (359.7 mg rutin equivalents/day)
Study: 21931228
Drug: Common buckwheat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common buckwheat cookies (16.5 mg rutin equivalents/day)
Study: 11054354
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination (5 microgram of recombinant hepatitis B vaccine, Engerix B) every 2 weeks up to a peak Ab titer of 1,000 IU/L or greater or 52 doses
Study: 11054354
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (40 microgram at 0, 1, 2, and 6 months)
Study: 11054354
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination with peak Ab titer of 1,000 IU/L or greater
Study: 8866093
Drug: Aprotinin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (high doses)
Study: 1339712
Drug: Allopurinol (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (oral, preoperatively)
Study: 6391936
Drug: Cisapride 5
Normalized name: cisapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 5 mg
Study: 6391936
Drug: Cisapride 4
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride 4 mg (IV)
Study: 6391936
Drug: Cisapride 8
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride 8 mg (IV)
Study: 6391936
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg (IV)
Study: 31608548
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin glargine 100 U/mL (Gla-100)
Study: 29498534
Drug: Nocturnal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal dexmedetomidine (0.2 μg/kg/h, titrated by 0.1 μg/kg/h every 15 min until a goal Richmond Agitation and Sedation Scale score of -1 or maximum rate of 0.7 μg/kg/h)
Study: 22668427
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg allicin adhesive tablets
Study: 19910620
Drug: Single-injection peribulbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection peribulbar anesthesia with a 16-mm needle
Study: 19910620
Drug: Double-injection peribulbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-injection peribulbar anesthesia with a 25-mm needle
Study: 8140047
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg administered orally
Study: 8140047
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg administered to the colon via nasogastric intubation
Study: 8140047
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg administered rectally using a retention enema
Study: 8140047
Drug: Nonparenteral routes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonparenteral routes (oral, colonic, rectal)
Study: 30621622
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin once per day (Group A)
Study: 30621622
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin and 4.0 g of ecabet sodium (Group B)
Study: 26742006
Drug: Tamoxifen 40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 40 mg daily for 2 or 5 years
Study: 26742006
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in patients with triple-negative and AR+ tumours
Study: 26742006
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in patients with AR- tumours
Study: 22583535
Drug: Drinking reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking reduction strategies during treatment
Study: 17242082
Drug: Magnetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic therapy (n = 81)
Study: 17242082
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (n = 84)
Study: 16075030
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure lowering using a fixed low-dose combination of perindopril and indapamide
Study: 12469525
Drug: Screening-tools for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening-tools for early identification and treatment of sleep-related breathing disorders
Study: 10440565
Drug: Aspirin 150
Normalized name: aspirin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 150 mg/d
Study: 479352
Drug: Aminoglutethimide (AG)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (AG) 1250 mg in divided doses
Study: 25282598
Drug: Buprenorphine/naloxone stabilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone stabilization and taper
Study: 19052048
Drug: CT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT group (low-dose CT screening)
Study: 12236276
Drug: Nitrofurantoin 100
Normalized name: nitrofurantoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 100 mg four times daily for three days
Study: 7813225
Drug: Low-dose biphasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose biphasic oral contraceptive (25 micrograms desogestrel and 40 micrograms ethinylestradiol for 7 days, followed by 125 micrograms desogestrel and 30 micrograms ethinylestradiol for 15 days)
Study: 7813225
Drug: Diane-35 (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane-35 (2.0 mg cyproterone acetate and 30 micrograms ethinylestradiol for 21 days)
Study: 2628304
Drug: Centpropazine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centpropazine 120 mg and above
Study: 2628304
Drug: Centpropazine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centpropazine 40 mg daily
Study: 2628304
Drug: Centpropazine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centpropazine 80 mg daily
Study: 624266
Drug: MAOI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAOI plus L-tryptophan
Study: 31924256
Drug: Routine rehabilitation
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine rehabilitation therapy
Study: 16908730
Drug: Argatroban (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (100 mug/kg bolus followed by 1 mug/kg/min infusion for 48 hours) combined with intravenous rtPA
Study: 10715521
Drug: pa vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pa vaccine
Study: 31529471
Drug: Fluorouracil 5%
Normalized name: FLUOROURACIL 5% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil 5% cream
Study: 29862491
Drug: Methyl aminolaevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl aminolaevulinate photodynamic therapy (MAL-PDT)
Study: 24918567
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate 0.015% gel
Study: 28888286
Drug: Information treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information treatment about funding opportunities for, and returns to, higher education (25-minute session)
Study: 26094929
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg eszopiclone per day
Study: 10854004
Drug: Chronic oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic oestrogen replacement therapy (ERT) 0.625 mg/day
Study: 10854004
Drug: Combined oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oestrogen and progestogen replacement therapy (HRT) ERT plus continuous medroxyprogesterone acetate 5 mg/day
Study: 31355944
Drug: Melatonin 25
Normalized name: calcium phosphate/melatonin 250 mg-1.5 mg ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 25 mg administered for twelve weeks
Study: 18024869
Drug: Four additional
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four additional cycles of third-generation, platinum-doublet treatment (arm A)
Study: 18024869
Drug: Two additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two additional cycles of third-generation, platinum-doublet treatment (arm B)
Study: 16209966
Drug: Enalapril (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5-10 mg)
Study: 16209966
Drug: Losartan (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (25-50 mg)
Study: 12585142
Drug: Xiaoyu Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoyu Tablet (XYT)
Study: 12585142
Drug: Gastrodine lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrodine lipid-lowering tablet
Study: 7862416
Drug: Balanced Salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced Salt Solution (BSS) Plus
Study: 7862416
Drug: Dextrose bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose bicarbonate lactated Ringer's solution
Study: 1772464
Drug: Hydrotalcite (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrotalcite (2 tablets qid, neutralizing capacity 122 mmol)
Study: 31604061
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of hyaluronic acid (8 mL, range 4 to 11 mL)
Study: 31604061
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of hyaluronic acid
Study: 27684740
Drug: Extended flexible
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended flexible regimen of 20 μg ethinylestradiol and 3 mg drospirenone (EE/DRSPe.flex)
Study: 27684740
Drug: 24/4 cyclical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24/4 cyclical regimen of the same formulation (EE/DRSP24/4)
Study: 25711648
Drug: General psychiatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: General psychiatric management (10-session treatment)
Study: 19808441
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (1 g of cefazolin administered intravenously before the procedure)
Study: 19808441
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no antibiotics administered)
Study: 14971661
Drug: Insoluble nickel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insoluble nickel compounds (Ni3S2, NiS, HT NiO, LT NiO)
Study: 18343244
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg TID
Study: 9448064
Drug: Sodium dichloroacetate
Normalized name: sodium dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium dichloroacetate (DCA) administered to healthy volunteers, specific dosage not mentioned.
Study: 8180032
Drug: Granisetron (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (any dose) with rescue doses
Study: 8180032
Drug: Granisetron alone
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron alone (any dose)
Study: 3358901
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg 12 hourly
Study: 3358901
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg 8 hourly
Study: 29216020
Drug: LP-pHF (1.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP-pHF (1.9 g protein/100 kcal)
Study: 29216020
Drug: Regular protein
Normalized name: PROTEIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular protein eHF (2.3 g protein/100 kcal)
Study: 28044986
Drug: 24-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 24-month dual antiplatelet therapy (DAPT)
Study: 22578254
Drug: Psilocybin (215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (215 μg/kg)
Study: 22578254
Drug: Ketanserin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (50 mg)
Study: 21131461
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine topical anesthetic cream applied to the face for one hour without occlusion (Group A)
Study: 21131461
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of 4% lidocaine applied to the face for one half-hour without occlusion (Group B)
Study: 21131461
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of 4% lidocaine applied to the face for one hour without occlusion (Group C)
Study: 21131461
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of 4% lidocaine applied to the face for one hour with occlusion (Group D)
Study: 16361531
Drug: FEC50 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC50 plus tamoxifen (fluorouracil 500 mg/m2, epirubicin 50 mg/m2, cyclophosphamide 500 mg/m2, six cycles every 21 days)
Study: 16361531
Drug: Tamoxifen alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen alone (30 mg/day, 3 years)
Study: 9272481
Drug: Ketamine (subanesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (subanesthetic doses)
Study: 6347755
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg three times a day)
Study: 6347755
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g three times a day)
Study: 4009965
Drug: slow-release nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow-release nifedipine (20 mg twice daily)
Study: 30032885
Drug: Ketamine 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0 mg kg‐1
Study: 30032885
Drug: Ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.25 mg kg‐1